iOrganBio Appoints AI and Life Sciences Investor Jessica Owens to Board of Directors

iOrganBio, an innovator in intelligent cell manufacturing, announced the appointment of Jessica Owens to its Board of Directors. Owens is a seasoned venture investor and serial founder with extensive experience building and scaling companies at the intersection of life sciences, health technology, and AI. Her appointment comes as iOrganBio focuses on scaling its CellForge platform, expanding partnerships, and advancing AI-driven cell manufacturing to improve predictability and scalability from model development to cell therapies.

Owens brings over 20 years of company-building and investing experience. She co-founded GRAIL, a healthcare company that raised over $1 billion and formed partnerships with Bristol Myers Squibb, Merck, and Johnson & Johnson. She also serves as co-founder and General Partner at Initiate Ventures. Her background in building and scaling companies in the life sciences and AI sectors is expected to provide invaluable counsel to iOrganBio as it grows.

iOrganBio is transforming human cell production with CellForge, its AI-powered platform for consistent, scalable, and intelligent manufacturing of cells and organoids for in vitro modeling and cell therapies. By applying engineering precision to biology, CellForge uses AI and automation to guide cell development and make real-time adjustments aligned with defined biological profiles. At the core of the platform is iOrganBio's functional human CellAtlas, a comprehensive reference built from single-cell and multi-omics data that provides the digital blueprints for each cell type. This smart, closed-loop process delivers the accuracy, efficiency, and quality needed to turn scientific ideas into breakthroughs, accelerating disease modeling, regenerative medicine, and drug development.

iOrganBio is based at BioLabs in Chapel Hill, NC. For more information, visit iOrgan.Bio.